Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides
Table 2
Medications, therapeutic effects, and exacerbation frequencies in DPB subjects with and without bronchiectasis during follow-up.
Treatment and outcome
Whole group ()
DPB with Bronchiectasis ()
DPB without Bronchiectasis ()
value▲
Macrolide antibiotics
0.572
Azithromycin
179 (82.5)
104 (80.6)
75 (85.2)
Clarithromycin
23 (10.6)
15 (11.6)
8 (9.1)
Erythromycin
12 (5.5)
7 (5.4)
5 (5.7)
Roxithromycin
3 (1.4)
3 (2.3)
0 (0)
Regular ICS + LABA
35 (16.1)
18 (14.0)
17 (19.3)
0.291
Regular LAMA
28 (12.9)
18 (14.0)
10 (11.4)
0.576
Follow-up period (months)
32.0 (18.5, 41.0)
35.5 (16.0, 45.0)
29.0 (21.0, 39.0)
0.192
Exacerbation frequency (time/year)■
0.5 (0, 1.5)
0.7 (0, 1.6)
0.3 (0, 1.3)
0.048
Treatment efficacy
<0.001
Healed
36 (16.6)
18 (20.5)
18 (14.0)
Improved
102 (47.0)
53 (60.2)
49 (38.0)
Unchanged
39 (18.0)
6 (6.8)
33 (25.6)
Deteriorating
32 (14.7)
7 (8.0)
25 (19.4)
Recurrent
8 (3.7)
4 (4.5)
4 (3.1)
Overall response
<0.001
Responsive
138 (63.6)
67 (51.9)
71 (80.7)
Unresponsive
79 (36.4)
62 (48.1)
17 (19.3)
Data are presented as median (interquartile range) or numbers (percentages). DPB: diffuse panbronchiolitis; ICS: inhaled corticosteroid; LABA: long-acting bronchial agonist; LAMA: long-acting muscarinic antagonist. ▲Comparison of DPB subjects with and without bronchiectasis. ■The exacerbation frequency (time/year) was defined as the number of exacerbation events/duration of follow-up (months) × 12.
